Inhibikase Therapeutics (DB:IQT0) - Stock Price, News & Analysis

IQT0 Stock Overview

A clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders.

IQT0 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 90.16% per year

Risk Analysis

Earnings are forecast to decline by an average of 14% per year for the next 3 years

Does not have a meaningful market cap (€7M)

Makes less than USD$1m in revenue ($252K)

Shares are highly illiquid

+ 3 more risks

Inhibikase Therapeutics, Inc. Competitors

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€31.5m

bioXXmed

XTRA:T5O

€698.7k

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Price History & Performance

Summary of all time highs, changes and price drops for Inhibikase Therapeutics
Historical stock prices
Current Share Price	US$0.56
52 Week High	US$5.61
52 Week Low	US$2.56
Beta	0.78
11 Month Change	0%
3 Month Change	-82.48%
1 Year Change	-89.58%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-98.26%

Recent updates

Shareholder Returns

	IQT0	DE Biotechs	DE Market
7D	0%	0.2%	-1.0%
1Y	-89.6%	-9.9%	12.8%

Return vs Industry: IQT0 underperformed the German Biotechs industry which returned -23.1% over the past year.

Return vs Market: IQT0 underperformed the German Market which returned 5.9% over the past year.

Price Volatility

Is IQT0's price volatile compared to industry and market?
IQT0 volatility
IQT0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.2%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.1%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: IQT0's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine IQT0's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2008	7	Milton Werner	www.inhibikase.com

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia.

Inhibikase Therapeutics, Inc. Fundamentals Summary

How do Inhibikase Therapeutics's earnings and revenue compare to its market cap?
IQT0 fundamental statistics
Market cap	€6.98m
Earnings (TTM)	-€18.01m
Revenue (TTM)	€238.24k

29.3x

P/S Ratio

-0.4x

P/E Ratio

Is IQT0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IQT0 income statement (TTM)
Revenue	US$251.79k
Cost of Revenue	US$13.43m
Gross Profit	-US$13.17m
Other Expenses	US$5.86m
Earnings	-US$19.03m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-3.56
Gross Margin	-5,232.12%
Net Profit Margin	-7,557.69%
Debt/Equity Ratio	0%

How did IQT0 perform over the long term?

See historical performance and comparison

IQT0 Stock Overview

Rewards

Risk Analysis

Inhibikase Therapeutics, Inc. Competitors

XTRA:CNW

€6.5m

XTRA:MDG1

€31.5m

XTRA:T5O

€698.7k

BST:BPXA

€772.4k

Price History & Performance

Recent News & Updates

Inhibikase Therapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.8 million.

Inhibikase Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Recent updates

Inhibikase Therapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.8 million.

Inhibikase Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.659255 million.

Inhibikase Therapeutics Announces Chief Financial Officer Changes, Effective End of the First Quarter of 2024

Inhibikase Therapeutics, Inc. Provides Update on Development Programs

Inhibikase Therapeutics, Inc. Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Inhibikase Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment

Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of Ikt-001Pro

Inhibikase Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Inhibikase Therapeutics Announces 1-For-6 Reverse Stock Split to Bring the Company into Compliance with Nasdaq's Minimum Bid Price Requirement

Inhibikase Therapeutics, Inc. Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

Inhibikase Therapeutics, Inc. Initiates Medical and Patient Awareness Campaign for Its Phase 2 '201' Trial Evaluating It-148009 in Parkinson's Disease

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.18 loss in 1Q 2022)

Inhibikase Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 23, 2023

Inhibikase Therapeutics, Inc. announced that it expects to receive $4.199512 million in funding

Inhibikase Therapeutics Announces Publication Demonstrating Potential for C-Abl as A Key Therapeutic Target in Parkinson's Disease and Related Disorders

Inhibikase Therapeutics, Inc. Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro

Inhibikase Therapeutics, Inc. Provides Update to FDA Clinical Hold of IkT-148009 Programs

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.18 loss in 3Q 2021)

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Inhibikase Therapeutics, Inc Announces FDA Clinical Hold on IkT-148009 Programs

High number of new and inexperienced directors

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. Announces Executive Changes

Inhibikase Therapeutics, Inc Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia

Inhibikase Therapeutics, Inc. Doses First Patient in Its Phase 2a '201' Clinical Trial of IKT-148009 to Treat Parkinson's Disease

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2021)

Inhibikase Therapeutics, Inc. to Report Q2, 2022 Results on Aug 12, 2022

Inhibikase Therapeutics Receives a Letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review

Inhibikase Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Full year 2021 earnings released: US$0.81 loss per share (vs US$0.35 loss in FY 2020)

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.082 loss in 3Q 2020)

Inhibikase Therapeutics, Inc. Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy

Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.052 loss in 2Q 2020)

Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell Microcap Value Index

Inhibikase Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $45 million.

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.067 loss in 1Q 2020)

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.067 loss in 1Q 2020)

Full year 2020 earnings released: US$0.35 loss per share (vs US$0.70 loss in FY 2019)

Inhibikase Therapeutics, Inc. Announces Update on Phase 1 Clinical Trial of IkT-148009

Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from NASDAQ Composite Index

Shareholder Returns

Price Volatility

About the Company

Inhibikase Therapeutics, Inc. Fundamentals Summary